Anurag Texofab (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.90 M
as on 23-10-2024
- Company Age 20 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 M
as on 23-10-2024
- Revenue -89.63%
(FY 2023)
- Profit -100.16%
(FY 2023)
- Ebitda -52.69%
(FY 2023)
- Net Worth -0.00%
(FY 2023)
- Total Assets 0.11%
(FY 2023)
About Anurag Texofab (India)
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.90 M.
The company currently has active open charges totaling ₹9.00 M.
Sumant Jalan and Sheetal Jalan serve as directors at the Company.
- CIN/LLPIN
U17118GJ2004PTC043436
- Company No.
043436
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Anurag Texofab (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumant Jalan  | Director | 07-Jan-2004 | Current |
| Sheetal Jalan | Director | 30-Aug-2020 | Current |
Financial Performance of Anurag Texofab (India).
Anurag Texofab (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 89.63% decrease. The company also saw a substantial fall in profitability, with a 100.16% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anurag Texofab (India)?
In 2023, Anurag Texofab (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Whitelotus Industries LimitedActive 13 years 8 monthsSumant Jalan and Sheetal Jalan are mutual person
- Dream Solve Cultivation And Marketing Private LimitedActive 14 years 7 months
Sumant Jalan and Sheetal Jalan are mutual person
- Laurel Infracon Private LimitedActive 15 years 9 months
Sumant Jalan and Sheetal Jalan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Ing Vysya Bank Limited Creation Date: 22 Dec 2006 | ₹9.00 M | Open |
How Many Employees Work at Anurag Texofab (India)?
Unlock and access historical data on people associated with Anurag Texofab (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anurag Texofab (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anurag Texofab (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
